EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors

Michael A Liu iD, Rohit Raghunathan, Karie Runcie, Margaux Wooster, Shikun Wang, Jason D Wright, Alexander Z Wei, Mark Stein, Dawn L Hershman iD

Cancer · 2025

DOI: 10.1002/cncr.70163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Michael A Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Receptor Antagonists. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Cancer Society, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Management of metastatic prostate cancer often requires combining androgen deprivation therapy (ADT) with novel androgen receptor signaling inhibitors (ARSIs). Although these agents improve survival, older patients may face acute care utilization from medication burden, reflected in polypharmacy and nonadherence.

Methods

Using SEER‐Medicare data, the authors identified patients ≥66 years old with de novo metastatic prostate cancer prescribed abiraterone, enzalutamide, or apalutamide (2010–2017). Polypharmacy was defined by the Youden index (≥8 medications). ARSI adherence was measured by medication possession ratio (≥0.8) from initiation to discontinuation, assessed over 6 months. Acute care use was defined as any inpatient hospitalization or emergency visit within 6 months. Demographic characteristics were compared by t ‐tests/χ 2 . Negative binomial regression estimated incidence rate ratios (IRRs) for acute care use.

Results

Among 2697 patients (mean age, 75 years), most were White (80.3%), married (63.1%), and received prior ADT (85.3%). Polypharmacy was present in 50.6% of patients before ARSI initiation, whereas ARSI nonadherence in the 6 months post‐initiation was 34.0%. Polypharmacy and adherence were not significantly associated. In adjusted analyses controlling for demographic, clinical, and treatment factors, both polypharmacy (IRR, 1.59; 95% confidence interval [CI], 1.28–1.98) and ARSI nonadherence (IRR 2.50; 95% CI, 2.00–3.03) independently prognosticated higher acute care use.

Conclusions

Medication burden, as characterized by suboptimal adherence and polypharmacy, is an independent risk factor for acute care use among older adults initiating ARSI treatment for metastatic prostate cancer. These findings highlight an opportunity for potential interventions to reduce downstream acute care use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen Receptor AntagonistsHumansMaleAgedNitrilesAged, 80 and overPolypharmacyPhenylthiohydantoinBenzamidesSEER ProgramMedicareThiohydantoinsUnited StatesAndrostenesNeoplasm MetastasisHospitalizationAndrogen Antagonists

Stichwörter der Autor:innen

acute care useandrogen receptor signaling inhibitorsmedication adherenceolder adultspolypharmacyprostate cancer

Substanzen

NitrilesenzalutamidePhenylthiohydantoinAndrogen Receptor AntagonistsBenzamidesabirateroneapalutamideThiohydantoinsAndrostenesAndrogen Antagonists

Autor:innen und Institutionen

  • Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.
  • Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Michael A Liu, Dawn L Hershman

Förderung

  • NCI NIH HHS
  • American Cancer Society
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Liu, M. A., Raghunathan, R., Runcie, K., Wooster, M., Wang, S., Wright, J. D., Wei, A. Z., Stein, M., & Hershman, D. L. (2025). Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. Cancer. https://doi.org/10.1002/cncr.70163

Vancouver

Liu MA, Raghunathan R, Runcie K, Wooster M, Wang S, Wright JD, et al. Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. Cancer. 2025. doi:10.1002/cncr.70163

BibTeX
@article{Liu2025,
  author = {Liu, Michael A and Raghunathan, Rohit and Runcie, Karie and Wooster, Margaux and Wang, Shikun and Wright, Jason D and Wei, Alexander Z and Stein, Mark and Hershman, Dawn L},
  title = {Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70163}
}
Kostenlos starten →